Tivic Health® Systems, Inc., a leading health tech company, has today announced the pricing of its highly anticipated public offering of 51,250,000 common shares. At a public offering price of $0.04 per share, the offering is expected to generate $2.1 million in gross proceeds before fees and expenses.
Tivic intends to use the net proceeds of the offering for working capital and general corporate purposes. The offering is seen as a step towards the advancement of bioelectronic medicine and marks a significant milestone in the Company’s growth trajectory.
Maxim Group LLC has been selected as the exclusive placement agent for this offering, offering their utmost commitment to making it a success. With their reasonable best efforts, they look forward to delivering a successful result.
The offering is set to close on July 19, 2023, pending the fulfillment of typical closing conditions. Don’t miss out on your chance to invest — seize this opportunity before it passes you by!
Tivic is revolutionizing the field of bioelectronic medicine with a patented technology platform designed to provide non-invasive and targeted therapies to treat inflammatory chronic health conditions. Their first commercial product, ClearUP, is an FDA approved, award-winning, handheld bioelectronic sinus device that is clinically proven, doctor-recommended, and available through online retailers and commercial distributors.
With its high safety profile and low risk, ClearUP is the go-to option for consumers and providers seeking drug-free therapeutic solutions with broad applications.